PL
HZNP

Polianta Ltd’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Polianta Ltd’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-33,500
Closed -$1.21M – 109
2019
Q4 		$1.21M Sell
33,500
-15,200
-31% -$466K 0.74% 18
2019
Q3 		$1.33M Buy
48,700
+9,700
+25% +$251K 0.84% 9
2019
Q2 		$938K Buy
+39,000
New +$989K 0.4% 69

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Polianta Ltd's HZNP Position: Q1 2020 in Review

Polianta Ltd sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 33,500 shares — an estimated $1.21M sold.

Polianta Ltd first reported a position in HZNP in Q2 2019 and held it in 3 quarters. The position peaked at $1.33M in Q3 2019. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

  • Polianta Ltd reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Polianta Ltd sold 33,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $1.21M.
  • Polianta Ltd first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 3 quarters.
  • Polianta Ltd's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.33M in Q3 2019.
  • 295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Polianta Ltd's 13F filing for Q1 2020, filed 7 Apr 2020.